Hi mmq, it is very difficult to control the share price of an...

Hi mmq,
it is very difficult to control the share price of an R&D company in the rare disease area (ie not a lot known and not many people aware) with no commercial activity.
The market has the greatest control, not the CEO.
In general, there is no magic bullet that indefinitely raises an R&D share price upward continually.
And in R&D if the price gets a surge then given time it generally retreats again, hence the ups and downs.
I have always wondered what people who continually complained about share price thought the CEO could do to maintain a permanent ascent.
Some companies can get lucky with circumstances, maybe they are in the right industry, at the right time, news breaks, or publicity comes or a big partner comes on board, but these are the exception, not the rule.
A large portion of Biotech R&D has had their share prices decimated in recent years, this isn't only ANP, it's the big boys too, look at IMU.

Whining achieves very little. If anything at all.